DYAI
Dyadic's Q4 2025 Earnings: A New Era of Commercialization
On March 25th, Dyadic Applied BioSolutions held its Full Year 2025 Conference Call, revealing a significant shift towards commercialization and revenue generation. This transformation marks a major milestone for the company, as it moves from a development stage platform to a product-driven biotechnology business. Joe Hazelton, President and COO of